Table 1 Baseline demographics and disease characteristics
| Â | SPIRIT-P1 and SPIRIT-P2 | |||
|---|---|---|---|---|
IXE Q4W | IXE Q2W | |||
No MTX/cDMARDs (N = 95) | MTXa (N = 85) | No MTX/cDMARDs (N = 82) | MTXa (N = 98) | |
Age, years | 51.2 (12.3) | 52.0 (12.4) | 52.0 (12.0) | 49.1 (11.7) |
Male, n (%) | 46 (48.4) | 41 (48.2) | 38 (46.3) | 44 (44.9) |
Weight, kg | 87.0 (22.6) | 87.2 (18.1) | 85.0 (21.9) | 83.3 (18.1) |
Time since PsA diagnosis, years | 10.5 (9.6) | 6.5 (6.6) | 9.2 (9.0) | 8.6 (7.0) |
Patients with specific disease characteristics, n (%) | ||||
 Enthesitisb | 53 (55.8) | 50 (58.8) | 53 (65.4)^ | 58 (59.8)f |
 Dactylitisc | 26 (27.4) | 22 (25.9) | 16 (19.5) | 23 (23.7)f |
 Current psoriasisd | 93 (97.9) | 80 (94.1) | 77 (93.9) | 91 (92.9)^^ |
Baseline disease and quality of life scores | ||||
 TJC (68 joints) | 21.8 (13.6) | 20.6 (15.1) | 25.2 (16.6) | 21.7 (15.1) |
 SJC (66 joints) | 12.4 (8.9) | 11.7 (10.8) | 13.7 (10.0) | 11.9 (8.1) |
 PGA VAS | 60.1 (19.3) | 57.9 (20.6) | 62.9 (19.1) | 61.9 (16.4) |
 PatGA VAS | 66.5 (18.8) | 64.0 (22.0) | 64.9 (21.4) | 63.8 (20.6) |
 Patients assessment of pain VAS | 63.0 (20.1) | 63.0 (21.6) | 61.5 (21.5) | 62.1 (21.7) |
 HAQ-DI | 1.2 (0.6) | 1.2 (0.6) | 1.2 (0.6) | 1.2 (0.6) |
 hsCRP, mg/L | 16.6 (27.0) | 15.2 (21.6) | 15.6 (29.3) | 14.1 (22.8) |
 PASI | 7.5 (8.6) | 6.3 (6.4) | 6.9 (7.9) | 6.0 (8.6) |
 % BSAe | 13.9 (18.8) | 14.9 (16.0) | 10.6 (14.7) | 13.1 (19.6) |